| Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis DHS Tan, MW Hull, D Yoong, C Tremblay, P O’byrne, R Thomas, J Kille, ... Cmaj 189 (47), E1448-E1458, 2017 | 230 | 2017 |
| Role of the pharmacist in caring for patients with HIV/AIDS: clinical practice guidelines A Tseng, M Foisy, CA Hughes, D Kelly, S Chan, N Dayneka, P Giguère, ... The Canadian journal of hospital pharmacy 65 (2), 125, 2012 | 85 | 2012 |
| Interactions between protease inhibitors and acid‐reducing agents: a systematic review L Béïque, P Giguère, C La Porte, J Angel HIV medicine 8 (6), 335-345, 2007 | 47 | 2007 |
| Evaluation of sodium polystyrene sulfonate dosing strategies in the inpatient management of hyperkalemia M Mistry, A Shea, P Giguère, ML Nguyen Annals of Pharmacotherapy 50 (6), 455-462, 2016 | 46 | 2016 |
| Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis DHS Tan, MW Hull, D Yoong, C Tremblay, P O’Byrne, R Thomas, J Kille, ... CMAJ 189 (47), E1448-E1458, 2017 | 45 | 2017 |
| CIHR Canadian HIV trials network coinfection and concurrent diseases core research group: 2016 updated Canadian HIV/hepatitis C adult guidelines for management and treatment M Hull, S Shafran, A Wong, A Tseng, P Giguère, L Barrett, S Haider, ... Canadian Journal of Infectious Diseases and Medical Microbiology 2016 (1 …, 2016 | 41 | 2016 |
| Psychiatric treatment considerations with direct acting antivirals in hepatitis C S Sockalingam, A Tseng, P Giguere, D Wong BMC gastroenterology 13, 1-10, 2013 | 38 | 2013 |
| A meta‐analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir‐boosted protease inhibitor maintenance therapy in HIV‐infected adults with … J Baril, B Conway, P Giguère, N Ferko, S Hollmann, JB Angel HIV medicine 15 (5), 301-310, 2014 | 33 | 2014 |
| Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications P Giguère, S Nhean, AL Tseng, CA Hughes, JB Angel Canadian Journal of Cardiology 35 (3), 326-340, 2019 | 29 | 2019 |
| Outcomes associated with reducing the urine alkalinization threshold in patients receiving high‐dose methotrexate SA Drost, JR Wentzell, P Giguère, DL McLurg, M Sabloff, S Kanji, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (6 …, 2017 | 27 | 2017 |
| Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis P Giguère, C la Porte, G Zhang, B Cameron Aids 23 (6), 740-742, 2009 | 25 | 2009 |
| Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia J Toy, P Giguère, S Kravcik, CJL la Porte Aids 25 (4), 541-542, 2011 | 23 | 2011 |
| Early experience with modified dose nirmatrelvir/ritonavir in dialysis patients with coronavirus disease 2019 S Hiremath, PG Blake, A Yeung, M McGuinty, D Thomas, J Ip, PA Brown, ... Clinical Journal of the American Society of Nephrology 18 (4), 485-490, 2023 | 22 | 2023 |
| CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults M Hull, M Klein, S Shafran, A Tseng, P Giguère, P Côté, M Poliquin, ... Canadian Journal of Infectious Diseases and Medical Microbiology 24 (4), 217-238, 2013 | 22 | 2013 |
| Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult AC Jacques, P Giguère, G Zhang, C Touchie, CJL la Porte Annals of Pharmacotherapy 44 (1), 202-206, 2010 | 21 | 2010 |
| Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV‐1‐infected patients RPG Van Heeswijk, M Bourbeau, I Seguin, P Giguere, GE Garber, ... British journal of clinical pharmacology 59 (4), 398-404, 2005 | 20 | 2005 |
| Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors N Shanil, H Nanci, G Pierre, B Andrew D HIV Clinical Trials 4 (3), 164-169, 2003 | 19 | 2003 |
| The efficacy of calcium carbonate in the treatment of protease inhibitor-induced persistent diarrhea in HIV-infected patients T Megan J, A Jonathan B, W Kirsten, G Pierre HIV Clinical Trials 5 (1), 19-24, 2004 | 17 | 2004 |
| Appropriateness of dabigatran and rivaroxaban prescribing for hospital inpatients U Chowdhry, A Jacques, A Karovitch, P Giguère, ML Nguyen The Canadian Journal of Hospital Pharmacy 69 (3), 194, 2016 | 16 | 2016 |
| CIHR Canadian HIV trials network co‐infection and concurrent diseases Core: updated Canadian guidelines for the treatment of hepatitis C infection in HIV‐hepatitis C coinfected … M Hull, S Shafran, A Tseng, P Giguère, MB Klein, C Cooper Canadian Journal of Infectious Diseases and Medical Microbiology 25 (6), 311-320, 2014 | 10 | 2014 |
